Albany Molecular Research, Inc. (NASDAQ:AMRI) Latest Broker Coverage
A number of investment brokers have recently updated their price targets on shares of Albany Molecular Research, Inc. (NASDAQ:AMRI). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
10/26/2015 – Albany Molecular Research, Inc. was upgraded to “overweight” by analysts at First Analysis. They now have a USD 25 price target on the stock.
02/17/2015 – Albany Molecular Research, Inc. had its “overweight” rating reiterated by analysts at Morgan Stanley. They now have a USD 19 price target on the stock.
11/10/2014 – Albany Molecular Research, Inc. was downgraded to “underperform” by analysts at Zacks. They now have a USD 16 price target on the stock.
11/06/2014 – Albany Molecular Research, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 22 price target on the stock.
07/07/2014 – Albany Molecular Research, Inc. had its “underperform” rating reiterated by analysts at Sterne Agee. They now have a USD 15 price target on the stock.
06/04/2014 – Albany Molecular Research, Inc. was upgraded to “buy” by analysts at TheStreet.
04/09/2014 – Albany Molecular Research, Inc. was upgraded to “underweight” by analysts at EVA Dimensions.
02/21/2014 – Albany Molecular Research, Inc. was upgraded to “buy” by analysts at McLean Capital Management.
The share price of Albany Molecular Research, Inc. (NASDAQ:AMRI) was down -4.92% during the last day of trading, with a day high of 15.16. 397915 shares were traded during the last session.
The stock’s 50 day moving average is 15.27 and its 200 day moving average is 17.02. The stock’s market capitalization is 493.25M. Albany Molecular Research, Inc. has a 52-week low of 13.71 and a 52-week high of 22.48.
View other investors thoughts on Albany Molecular Research, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.